12794-19-3

Basic information

• Product Name: (+)-3,4,6,11-Tetrahydro-10,12-dihydroxy-3,6,11-trioxo-1H-anthra[2,3-c]pyran-1-acetamide
• Synonyms: (+)-3,4,6,11-Tetrahydro-10,12-dihydroxy-3,6,11-trioxo-1H-anthra[2,3-c]pyran-1-acetamide;(+)-Ekatetrone
• CAS NO: 12794-19-3
• Molecular Formula: C19H13 N O7
• Molecular Weight: 367.309
• Mol File: 12794-19-3.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 742.7°Cat760mmHg
• Flash Point: 403°C
• Appearance: /
• Density: 1.606g/cm³
• Vapor Pressure: 8.2E-23mmHg at 25°C
• Refractive Index: 1.708
• PKA: 5.61±0.40(Predicted)
• CAS DataBase Reference: (+)-3,4,6,11-Tetrahydro-10,12-dihydroxy-3,6,11-trioxo-1H-anthra[2,3-c]pyran-1-acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-3,4,6,11-Tetrahydro-10,12-dihydroxy-3,6,11-trioxo-1H-anthra[2,3-c]pyran-1-acetamide(12794-19-3)
• EPA Substance Registry System: (+)-3,4,6,11-Tetrahydro-10,12-dihydroxy-3,6,11-trioxo-1H-anthra[2,3-c]pyran-1-acetamide(12794-19-3)

Safety Data

• Hazardous Substances Data: 12794-19-3(Hazardous Substances Data)

Usage

General Description

(+)-3,4,6,11-Tetrahydro-10,12-dihydroxy-3,6,11-trioxo-1H-anthra[2,3-c]pyran-1-acetamide, also known as daunorubicin, is a type of anthracycline antibiotic and chemotherapy medication used to treat various types of cancer, including leukemia, lymphoma, and solid tumors. It works by interfering with the growth and spread of cancer cells in the body. Daunorubicin is typically administered intravenously and is often used in combination with other cancer medications to enhance its effectiveness. However, it can have serious side effects, including damage to the heart and bone marrow suppression, and should only be used under the supervision of a qualified healthcare professional.

InChI:InChI=1/C19H13NO7/c20-12(22)6-11-14-7(5-13(23)27-11)4-9-16(18(14)25)19(26)15-8(17(9)24)2-1-3-10(15)21/h1-4,11,21,25H,5-6H2,(H2,20,22)